Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AZT.OL
- Price
- 21.60
- Stock movement up
- +0.40 (1.89%)
- Company name
- Arcticzymes Technologies ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.10B
- Ent value
- 942.66M
- Price/Sales
- 10.70
- Price/Book
- 3.34
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 143.98
- Forward P/E
- 48.30
- PEG
- -
- EPS growth
- -
- 1 year return
- 60.00%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-12
DIVIDENDS
AZT.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 143.98 |
| Price to OCF | 58.59 |
| Price to FCF | 174.41 |
| Price to EBITDA | 154.00 |
| EV to EBITDA | 131.68 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 10.70 |
| Price to Book | 3.34 |
| EV to Sales | 9.15 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 51.04M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | 0.45 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 182.30M |
| Net receivables | 13.34M |
| Total current assets | 296.13M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 18.35M |
| Total assets | 352.97M |
| Accounts payable | 4.07M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 18.11M |
| Total liabilities | 22.50M |
| Shareholder's equity | 330.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 21.30 |
| Daily high | 21.90 |
| Daily low | 20.70 |
| Daily Volume | 93K |
| All-time high | 111.00 |
| 1y analyst estimate | 32.00 |
| Beta | 0.37 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Feb 2026 |
Downside potential
Loading...
Downside potential data
| AZT.OL | S&P500 | |
| Current price drop from All-time high | -80.54% | -1.08% |
| Highest price drop | -88.52% | -19.00% |
| Date of highest drop | 29 Nov 2024 | 8 Apr 2025 |
| Avg drop from high | -82.85% | -2.64% |
| Avg time to new high | - | 6 days |
| Max time to new high | 297 days | 89 days |
COMPANY DETAILS
Marketcap
1.10B
Marketcap category
Small-cap
Description
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools, such as research and diagnostics, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Employees
53
Website
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
ArcticZymes Technologies ASA (LTS:0DRV) reports a 24% revenue increase and strategic initiatives for future expansion despite challenges in key markets.
November 6, 2025
As the European stock markets continue to show resilience with the pan-European STOXX Europe 600 Index rising by 1.68% and major indices such as Germany's DAX and the UK's FTSE 100 also posting gains,...
October 28, 2025
As European markets continue to show resilience with the STOXX Europe 600 Index and major stock indexes on the rise, investors are keenly observing opportunities amid steady inflation rates and strong...
October 28, 2025
As European markets experience a notable upswing, with the STOXX Europe 600 Index and major national indices showing gains, investors are increasingly attentive to opportunities that may arise from th...
October 27, 2025
In recent weeks, the European markets have shown mixed performance, with the pan-European STOXX Europe 600 Index inching higher amid dovish comments from U.S. Federal Reserve Chair Jerome Powell and e...
October 23, 2025
As European markets navigate a mixed landscape, with the STOXX Europe 600 Index inching higher amid dovish signals from the U.S. Federal Reserve and easing trade tensions, investors are keenly observi...
October 23, 2025
In a week marked by volatility, global markets showed resilience as U.S. stocks rebounded and dovish signals from the Federal Reserve provided some support, despite ongoing concerns about trade tensio...
October 21, 2025
As the European market navigates a mixed landscape with the STOXX Europe 600 Index inching higher amid dovish signals from U.S. Federal Reserve officials, investors are closely monitoring economic ind...
October 21, 2025
The European stock market has recently seen a positive trend, with the pan-European STOXX Europe 600 Index rising 2.11% amid strong corporate earnings and optimism surrounding geopolitical resolutions...
August 14, 2025
In recent weeks, global markets have experienced notable movements, with the U.S. Nasdaq Composite reaching an all-time high and European indices climbing on strong corporate earnings and geopolitical...
August 14, 2025
Next page